<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04897750</url>
  </required_header>
  <id_info>
    <org_study_id>PDC 01-0206</org_study_id>
    <nct_id>NCT04897750</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Intranasal CT001 in Children 1-17 Years of Age Undergoing Elective Surgical Procedures</brief_title>
  <official_title>Pharmacokinetic Study of Intranasal CT001 in Children 1-17 Years of Age Undergoing Elective Surgical Procedures.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cessatech A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cessatech A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective non-randomized, open-label, single dose (and a second dose if needed),&#xD;
      PK study in 25 children age 1-17 years. The proposed number of study participants by subset&#xD;
      is: 8 paediatric participants 1-2 years; 8 paediatric participants &gt;2-6 years and 9&#xD;
      paediatric participants &gt;6-17 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study population will receive a target dose of intranasal CT001 corresponding to sufentanil 0.5 mcg/kg + ketamine 0.5 mg/kg (and an additional dose 10 -15 minutes after, if needed) prior to an elective surgical, procedure.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total absorption over time</measure>
    <time_frame>0 - 120 minutes</time_frame>
    <description>Area under the concentration vs time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum absorption</measure>
    <time_frame>0 - 120 minutes</time_frame>
    <description>Peak concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution</measure>
    <time_frame>120 - 240 minutes</time_frame>
    <description>Volumen of distribution (Vd)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination</measure>
    <time_frame>120 - 240 minutes</time_frame>
    <description>Half life (T½)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination</measure>
    <time_frame>120 - 240 minutes</time_frame>
    <description>Clearance,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgetic effect</measure>
    <time_frame>0 - 1 hour</time_frame>
    <description>pain intensity by age-appropriate scale in relation to the placement of peripheral venous catheter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation</measure>
    <time_frame>0 - 1 hour</time_frame>
    <description>Assessment of sedation at the time of placement of the peripheral venous catheter using the University of Michigan Sedation Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility, (Acceptance of intranasal administration)</measure>
    <time_frame>0- 4 hours</time_frame>
    <description>Acceptance of the intranasal route of administration by the child, assessed by the child or legally acceptable representative or health care provider.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a target dose of intranasal sufentanil 0,5 mcg/kg + ketamine 0,5 mg/kg, (2-4 puffs) and an additional dose if needed as premedication before placement of a PVC for induction of anaesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>CT001</intervention_name>
    <description>Sufentanil 0.5 mcg/kg + ketamine 0.5 mg/kg as nasal spray, followed by an additional dose 10 -15 minutes after, if needed.</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Paediatric participants, age 1-17 years at the day of the surgical procedure&#xD;
&#xD;
          -  Planned for elective surgical procedures (e.g. hernia, orchiopexy, gastroscopy,&#xD;
             cystoscopy)&#xD;
&#xD;
          -  ASA (American Society of Anaesthesiologists) physical status classification system&#xD;
             score 1-2 as determined by investigator&#xD;
&#xD;
          -  Planned for induction of anaesthesia by an intravenous anaesthetic agent, requiring&#xD;
             placement of peripheral venous catheter immediately prior to the surgical procedure&#xD;
&#xD;
          -  Needs premedication before induction of anaesthesia as determined by investigator&#xD;
&#xD;
          -  Informed consent by the legally acceptable representative(s)&#xD;
&#xD;
          -  The legally acceptable representative(s) and patients 15-17 years must be able to&#xD;
             understand and speak local language&#xD;
&#xD;
          -  A female participant who has onset of menarche is eligible to participate if she is&#xD;
             not pregnant, not breastfeeding and agree to follow the contraceptive guidance during&#xD;
             the treatment period for at least 7 days after administration of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ex-premature infant (born &lt;37 weeks AND less than 60 weeks post conceptual age at the&#xD;
             day of the surgical procedure)&#xD;
&#xD;
          -  Mental retardation&#xD;
&#xD;
          -  Abnormal nasal cavity or nasal obstruction&#xD;
&#xD;
          -  Clinical contraindications to narcotic analgesia including head injury or any&#xD;
             condition that can in the opinion of the investigator, deteriorate safety and&#xD;
             well-being of the participants, influence PK data or optimal participation in the&#xD;
             trial&#xD;
&#xD;
          -  Medical history including substance or alcohol abuse&#xD;
&#xD;
          -  Has received treatment with sufentanil and/or ketamine during the last 72 hours prior&#xD;
             to surgery&#xD;
&#xD;
          -  Has planned perioperative administration of sufentanil and/or ketamine&#xD;
&#xD;
          -  Has or is suspected of having a family or personal history of malignant hyperthermia&#xD;
&#xD;
          -  Has or is suspected of having allergies to ketamine or sufentanil&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Classen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anaesthesiology, The Juliane Marie Centre Copenhagen University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steen Henneberg, MD, P.HD</last_name>
    <phone>+45 25784942</phone>
    <email>steen.henneberg@cessatech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jes Trygved</last_name>
    <phone>+45 93872309</phone>
    <email>jes.trygved@cessatech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anæstesi- og Operationsafdelingen 4013 Juliane Marie Centeret</name>
      <address>
        <city>Copenhagen</city>
        <state>Region H</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Classen, Dr.Med</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 14, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

